Holen Sie sich die Stockscreener-App
46.95
1.55%
-0.74
Handel nachbörslich:
47.55
0.60
+1.28%
Schlusskurs vom Vortag:
$47.69
Offen:
$46.9
24-Stunden-Volumen:
2.27M
Relative Volume:
1.20
Marktkapitalisierung:
$4.51B
Einnahmen:
$3.51M
Nettoeinkommen (Verlust:
$-581.60M
KGV:
-7.207
EPS:
-6.5145
Netto-Cashflow:
$-345.93M
1W Leistung:
-3.93%
1M Leistung:
-14.07%
6M Leistung:
-24.66%
1J Leistung:
+11.95%
1-Tages-Spanne:
$46.32
$48.20
1-Wochen-Bereich:
$46.32
$50.19
52-Wochen-Spanne:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
46.95 | 4.58B | 3.51M | -581.60M | -345.93M | -6.5145 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Here is why CRISPR Therapeutics (CRSP) appears so good - MSN
CRISPR Therapeutics AG (CRSP) Declines Sharply Compared to Overall Market: Essential Information for Investors - Bitget
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo! Finance Canada
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - MSN
CRISPR Therapeutics AG Bonds — Corporate Bond Rates - TradingView
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - MSN
(CRSP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Piper Sandler raises CRISPR Therapeutics price target on cash raise By Investing.com - Investing.com South Africa
Volatility Watch: Is CRISPR Therapeutics AG showing insider buyingInsider Selling & Proven Capital Preservation Tips - baoquankhu1.vn
CRISPR Therapeutics (CRSP) Is Down 5.1% After $550M Convertible Notes OfferingHas The Bull Case Changed? - simplywall.st
Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,349 Shares of Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Insider Naimish Patel Sells 3,150 Shares of Stock - MarketBeat
CRISPR Therapeutics (NASDAQ: CRSP) CMO vests RSUs, mandated tax sale - Stock Titan
CRISPR Therapeutics (NASDAQ: CRSP) CFO covers RSU taxes with share sale and gift - Stock Titan
CRISPR Therapeutics (NASDAQ: CRSP) GC sells shares for tax withholding - Stock Titan
CRISPR Therapeutics (CRSP) CEO logs RSU vesting and tax-driven share sale - Stock Titan
Crispr Therapeutics Completes $600 Million Convertible Notes Offering - The Globe and Mail
Goodwin Guides CRISPR Therapeutics On Pricing $550 Million Upsized Convertible Senior Notes Offering - Mondaq
Piper Sandler Raises Price Target for CRSP to $110, Reiterates O - GuruFocus
Is CRISPR Therapeutics (CRSP) the best gene-editing stock to buy now? - MSN
Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now? - Insider Monkey
CRISPR Therapeutics (NASDAQ:CRSP) Receives Overweight Rating from Piper Sandler - MarketBeat
Piper Sandler raises CRISPR Therapeutics price target on cash raise - Investing.com
CRISPR Therapeutics (NASDAQ: CRSP) sells $600M 2031 convertible notes - Stock Titan
CRISPR Therapeutics AG Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ark Invest Increases Holdings in CRISPR Therapeutics (CRSP) - GuruFocus
Clough Capital Partners L P Makes New $1.49 Million Investment in CRISPR Therapeutics AG $CRSP - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
CRISPR Therapeutics prices $550M convertible notes offering By Investing.com - Investing.com Nigeria
Is CRISPR Therapeutics (CRSP) Pricing Reflecting Gene Editing Potential After Recent Share Pullback - Yahoo Finance
CRISPR Therapeutics’ CASGEVY Progress Reframes Growth And Valuation Story - Sahm
CRISPR Therapeutics shares drop after announcing convertible notes sale - MSN
Cathie Wood’s ARK Invest Buys $10M in CRISPR and PayPay on Thursday - MEXC
ARK Invest Allocates $10M to CRISPR Therapeutics and PayPay in Latest Trading Session - MEXC
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - Yahoo Finance
Q2 EPS Estimate for CRISPR Therapeutics Lifted by Analyst - MarketBeat
Assessing CRISPR Therapeutics (CRSP) Valuation After Upsized US$550m Convertible Notes Offering - Sahm
Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest? - MSN
ARK Investment Acquires 113K Shares of Crispr Therapeutics (CRSP) - GuruFocus
Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells 2,800 Shares of Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 9,798 Shares - MarketBeat
CRISPR Therapeutics AG CEO Samarth Kulkarni Sells Shares - TradingView
CRISPR Therapeutics (CRSP) counsel sells 2,800 shares to cover RSU taxes - Stock Titan
CRISPR Therapeutics (CRSP) CEO RSU vesting and 9,798-share tax sale - Stock Titan
CRISPR Therapeutics plans $350M convertible notes offering By Investing.com - Investing.com Nigeria
Research Analysts Set Expectations for CRSP FY2028 Earnings - MarketBeat
CRISPR Therapeutics AG (CRSP) Falls Sharper Than Overall Market: Key Information to Note - Bitget
CRISPR Therapeutics AG (CRSP) dips more than broader market: What you should know - MSN
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know - Yahoo Finance
CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth - Insider Monkey
CRISPR Therapeutics Announces $350 Million Convertible Senior Notes Offering to Fund Gene-Editing Innovation - Minichart
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.20%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):